Cargando…
MAO-inhibitors in Parkinson's Disease
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD). They have been used with or without levodopa (L-DOPA). Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment of depression...
Autores principales: | Riederer, Peter, Laux, Gerd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Brain and Neural Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213739/ https://www.ncbi.nlm.nih.gov/pubmed/22110357 http://dx.doi.org/10.5607/en.2011.20.1.1 |
Ejemplares similares
-
Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007) -
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013) -
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022) -
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016) -
Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
por: Krishna, Rakhee, et al.
Publicado: (2014)